Telotristat etiprate, or LX1032, is an orphan drug being developed by Lexicon Pharmaceuticals for the treatment of patients with carcinoid cyndrome. In this exclusive interview with Rare Disease Report, Pablo Lapuerta, MD, chief medical officer at Lexicon Pharmaceuticals discusses the phase 3 clinical trials underway to test the safety and efficacy of telotristat etiprate in patients with carcinoid syndrome.
To learn more about this condition, visit [ Ссылка ]
